Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00414960 · ClinicalTrials.gov registry record · Phase 2
A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00414960 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 40 participants.
The verdict
NCT00414960, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
To compare the difference of a marker of cellular proliferation in all bronchial biopsy specimens of former smokers stratified by lung cancer risk, collected before and after treatment per patient between the enzastaurin and placebo groups.
Interventions
- DRUG Placebo
- DRUG Enzastaurin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00414960
The ClinicalTrials.gov registry entry for NCT00414960 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00414960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00414960 about?
NCT00414960 is a clinical study titled "A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers". To compare the difference of a marker of cellular proliferation in all bronchial biopsy specimens of former smokers stratified by lung cancer risk, collected before and after treatment per patient between the enzastaurin and placebo groups.
What is the current status of trial NCT00414960?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2007-12. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00414960?
The interventions under investigation include: Placebo (DRUG), Enzastaurin (DRUG).
Who is sponsoring clinical trial NCT00414960?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.